![Ruth Adams](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Ruth Adams worked as Head-Clinical Operation at Vigeo Therapeutics, Inc. Ms. Adams worked as Vice President-Clinical Operations at Nuvalent, Inc. from 2020 to 2026.
Ms. Adams completed undergraduate education at The University of Southampton.
Ehemalige bekannte Positionen von Ruth Adams
| Unternehmen | Position | Ende |
|---|---|---|
| NUVALENT, INC. | Technik-/Wissenschafts-/F&E-Leiter | 15.07.2026 |
Vigeo Therapeutics, Inc.
 Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cancer drugs | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Ruth Adams
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
30
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
The University of Southampton
 The University of Southampton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vigeo Therapeutics, Inc.
Vigeo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures cancer drugs | Health Technology |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
